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None of the five mutations identified during the in vitro selection experiments was detected among the 132 sequences, either in majority or minority proportion. Regarding the 14 samples obtained at time of VF, no selection of any of these five mutations was observed.
The present study, performed on a large dataset of CA sequences obtained from antiretroviral-naive patients and representing a variety of HIV-1 group M subtypes, showed the absence in pre-therapeutic samples of the five GS-CA1 resistanceassociated mutations recently described in vitro.
The newest antiretroviral classes still under development, such as attachment or maturation inhibitors, can be impacted by the presence of pre-existing mutations. Thus, gag cleavage site mutations decreased susceptibility to the first generation of maturation inhibitors. 5, 6 Similarly, in vitro phenotypic susceptibility of attachment inhibitors can be impaired by the presence of pre-existing mutations in the CD4 binding site. 7, 8 However, regarding the CAI drug class, particularly GS-CA1, our findings suggest no need for pre-therapeutic genotypic resistance testing before using the first compound of this new antiretroviral drug class, which is currently at the preclinical development stage. Sir, We report on the case of an HIV/HCV-coinfected patient in her mid-40s with porphyria cutanea tarda (PCT) treated with sofosbuvir/ledipasvir who achieved a sustained virological response (SVR) despite a mixed HCV infection with two different subtypes.
Her coinfection dated back to 1991, after intravenous drug abuse. Since 1995 she had undergone different ART regimens, maintaining adherence and good response from 2004. Until 2015 her laboratory analyses revealed only sporadic minimal increases in transaminases and she remained asymptomatic.
In August 2015, while on treatment with oestrogens and emtricitabine/tenofovir/nevirapine, with a CD4 count of 1057 cells/mm 3 and with an undetectable viral load, she presented itching vesicular hand skin lesions, evolving to crusting and scarring. Blood analysis demonstrated a slight increase in transaminases (AST, 45 U/L; ALT, 46 U/L) and normal iron (111 lg/L) and ferritin (78 lg/L) levels. In-depth analysis revealed high urinary porphyrin levels, with a pattern suggestive of PCT (Table 1) ; she was an ex-smoker and she did not report alcohol abuse. These data suggested a diagnosis of PCT potentially triggered by HCV chronic infection. Despite limitation of sun exposure, use of appropriate ultraviolet protection and interruption of oestrogen treatment, no clinical remission was observed. In November 2015, she started low-dose chloroquine (125 mg twice weekly) with no clinical improvement demonstrated by the persistence of skin lesions and the high uroporphyrin levels ( Table 1 ). The well-known association of HCV chronic infection and development of PCT as an extra-hepatic manifestation in treatment-naive patients allowed us to start an eradicating treatment, in spite of F0 stiffness, according to current national regulations in the matter of direct-acting antiviral (DAA) use. 1 At pretreatment genotype assessment, the INNO-LiPA TM HCV II kit (Innogenetics, Ghent, Belgium) showed a dual HCV infection (subtypes 1a and 1b). Phylogenetic analysis of a conserved fragment within the NS5B region (nt 8281-8679) identified only the subtype 1a virus, whilst the complete NS3/4, NS5A and NS5B virus sequences, using subtype-specific primers, confirmed the presence of dual infection. 2, 3 Moreover, the NS3 sequences showed 36L (99.8%) and 80K (97.5%) resistance-associated substitutions (RASs) in subtype 1a virus and 170I in subtype 1b. 3 No RAS was found in the NS5A sequence for subtype 1a virus, whilst 28M was found for subtype 1b. NS5B sequences showed 444D and 159F/316N/556G RAS in subtypes 1a and 1b, respectively. The results were confirmed in two different samples from the patient. Sentosa V R SQ next-generation sequencing (NGS) (Vela Diagnostics, GmBH, Hamburg, Germany) analysis was performed. NGS reads were aligned to both HCV subtype 1a (NC_004102) and 1b (EU256045) reference genomes and also against sequences 1a and 1b obtained from patient samples using BWA (Version 0.7.12.1) implemented in the online data analysis platform Galaxy (public web access: http://usegalaxy. org). As expected, the number of mapped reads was higher when compared with patient sequences with respect to reference genomes. Molecular analysis is shown in Figure 1 .
IL-28B rs.12979860 and rs.8099917 SNPs resulted in CT and TG, respectively.
In February 2016 she started sofosbuvir/ledipasvir without ribavirin; HCV-RNA was 1.5%10 6 IU/mL at baseline and became undetectable on day 3 of treatment. SVR was maintained despite RAS presence at baseline. 4 Both cutaneous manifestations and urinalysis showed a concurrent improvement (Table 1) . At the end of treatment chloroquine was withdrawn. At the latest visit, 48 weeks after HCV undetectability, the patient showed no skin lesions at all. Porphyrin levels were the lowest since diagnosis, close to normality.
The introduction of DAAs represents a breakthrough achievement in the management of HIV/HCV coinfection. The two infections are known to negatively affect each other's course, as well as comorbidities. HCV eradication may therefore give additional benefits in a coinfected individual, the more so if associated diseases are also present.
The association between HCV and the development of the sporadic form of PCT is well known; 5, 6 besides HCV, also HIV, alcohol abuse, oestrogen use, smoking and iron intake are considered risk factors for the development of porphyria. In our patient, however, HCV chronic infection seemed the most important considering the outcome; furthermore, the identification of a dual HCV infection increases the peculiarity of the case. As recently reported, the introduction of DAAs for HCV virus seems to better improve the resolution of PCT manifestations with respect to the previously used interferon/ribavirin-based regimens. [5] [6] [7] DAAs used to treat HCV infection act in a genotype-specific manner; therefore, responsiveness to HCV virus could vary significantly with genotypes. Even in the presence of multiple adverse prognostic markers, e.g. several RAS in both viruses, we observed that a mixed HCV infection can rapidly respond to potent antiviral therapy.
As far as we know, this is the first case of HIV/dual HCV infection treated for an extra-hepatic manifestation with an excellent response to DAA therapy. Our experience highlights the promising role of DAAs in mixed HCV infections and in the management of cutaneous extra-hepatic manifestations such as PCT.
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